Similar articles

• [Percutaneous coronary interventions. Guidelines of the European Society of Cardiology-ESC].

  Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyłło W, Urban P, Stone GW, Wijns W; European Society of Cardiology. Silber S, et al. Kardiol Pol. 2005 Sep;63(3):265-320; discussion 321-3. Kardiol Pol. 2005. PMID: 16180183 Review. Polish. No abstract available.
• Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.

  Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, Jørgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W; Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Silber S, et al. Eur Heart J. 2005 Apr;26(8):804-47. doi: 10.1093/eurheartj/ehi138. Epub 2005 Mar 15. Eur Heart J. 2005. PMID: 15769784
• Glycoprotein IIb/IIIa inhibition in percutaneous coronary interventions.

  Sharma S, Nyitray W, Bhambi B. Sharma S, et al. JAMA. 2003 Sep 17;290(11):1451; author reply 1451. doi: 10.1001/jama.290.11.1451-a. JAMA. 2003. PMID: 13129974 No abstract available.
• Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.

  Goldschmidt-Clermont PJ. Goldschmidt-Clermont PJ. J Invasive Cardiol. 2002 Dec;14 Suppl E:1E. J Invasive Cardiol. 2002. PMID: 12668856 No abstract available.
• Antithrombotic therapy in patients undergoing percutaneous coronary intervention.

  Popma JJ, Ohman EM, Weitz J, Lincoff AM, Harrington RA, Berger P. Popma JJ, et al. Chest. 2001 Jan;119(1 Suppl):321S-336S. doi: 10.1378/chest.119.1_suppl.321s. Chest. 2001. PMID: 11157657 Review. No abstract available.